CJC / Ipamorelin
CJC-1295 and Ipamorelin are two different peptides that influence growth-hormone signaling through different pathways. CJC-1295 acts as a growth-hormone-releasing hormone analog, while Ipamorelin acts as a growth-hormone secretagogue. Treatment decisions at New Horizon Wellness are individualized and provider-guided.
What Is CJC / Ipamorelin?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). Human studies of CJC-1295 have shown that it can increase circulating growth hormone and IGF-1 levels for an extended period.
Ipamorelin is a growth-hormone-releasing peptide that acts through the ghrelin receptor. Human pharmacology studies have demonstrated a short-lived pulse of growth-hormone release after administration.
Although these compounds are frequently discussed together, clinical evidence on the combined CJC-1295 / Ipamorelin regimen is much more limited than the evidence studying each compound separately.
Two Different Signaling Pathways
CJC-1295
- Acts as a synthetic analog of GHRH
- Stimulates pituitary growth-hormone release
- Human studies have demonstrated increases in GH and IGF-1
- The long-acting form studied clinically produced sustained effects
Ipamorelin
- Acts as a growth-hormone secretagogue
- Signals through the ghrelin receptor
- Produces a measurable growth-hormone pulse in human studies
- Has a substantially shorter pharmacologic duration than long-acting CJC-1295
What Does the Research Show?
In randomized studies of healthy adults, CJC-1295 produced dose-dependent increases in growth hormone and IGF-1. One published trial reported elevated growth hormone for several days and elevated IGF-1 for approximately nine to eleven days after a single dose of long-acting CJC-1295.
Ipamorelin has also been studied in human volunteers. Pharmacokinetic research showed a dose-related growth-hormone response with a relatively short terminal half-life and a single growth-hormone pulse after administration.
These studies establish biological activity, but they do not establish that the commonly marketed CJC / Ipamorelin combination improves body composition, sleep, recovery, performance, or healthy aging. High-quality clinical outcome data for the combination remain limited.
Why Patients Ask About CJC / Ipamorelin
Goals commonly discussed include:
- Recovery and performance goals
- Body-composition concerns
- Sleep and wellness goals
- Interest in growth-hormone signaling and IGF-1
- Broader healthy-aging or wellness planning
These are discussion areas, not FDA-approved indications or guaranteed treatment outcomes.
What to Know
CJC-1295 and Ipamorelin are not FDA-approved drugs for the wellness uses commonly promoted online. Human clinical data remain limited, particularly for the combined regimen.
FDA has identified safety concerns related to compounded CJC-1295, including reported increased heart rate and systemic vasodilatory reactions. FDA has also identified limited safety information and potential immunogenicity concerns for injectable Ipamorelin.
A provider should review your health history, medications, laboratory findings, treatment goals, and alternatives before any therapy is considered.
Interested in CJC / Ipamorelin?
Schedule a consultation to discuss your goals, current health, laboratory findings, and available treatment options.